NCT05129423 is a Phase 2 clinical trial of MTPS9579A in Chronic Spontaneous Urticaria, sponsored by Genentech, Inc..

Who is sponsoring NCT05129423?

NCT05129423 is sponsored by Genentech, Inc..

What drugs are being tested in NCT05129423?

Interventions in NCT05129423: MTPS9579A, Placebo.

What condition does NCT05129423 study?

NCT05129423 studies Chronic Spontaneous Urticaria.

Is NCT05129423 still recruiting?

NCT05129423 is currently withdrawn. Last updated 18 November 2022.

Last reviewed 2022-11-18 · How we verify

NCT05129423

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria

Withdrawn Phase 2 Last updated 18 November 2022

What this trial tests

Phase 2 trial testing MTPS9579A in Chronic Spontaneous Urticaria. Withdrawn.

Timeline

31 July 2022

Primary endpoint
31 July 2024

31 August 2024

Quick facts

Lead sponsor	Genentech, Inc.
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Start date	31 July 2022
Primary completion	31 July 2024
Estimated completion	31 August 2024

Drugs / interventions tested

MTPS9579A — full drug profile →
Placebo

Conditions studied

Chronic Spontaneous Urticaria — all drugs for Chronic Spontaneous Urticaria →

Sponsor

Genentech, Inc. — full company profile →

Who can join

Adults 18 to 75, any sex, with Chronic Spontaneous Urticaria. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot and dose-ranging study will evaluate the efficacy, safety, and pharmacokinetics of MTPS9579A compared with placebo in participants with chronic spontaneous urticaria (CSU) refractory to antihistamines. This study comprises two parts. In Part 1, participants will be randomized to receive MTPS9579A or placebo. On the basis of positive results from Part 1, a dose-ranging Part 2 may be opened, where participants will be randomized to receive one of four MTPS9579A doses or placebo.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma.
Hu M, Scheffel J, Elieh-Ali-Komi D, Maurer M, et al · · 2023 · cited 10× · PMID 37555911 · DOI 10.1007/s10238-023-01141-x
Monoclonal Antibodies in Treating Chronic Spontaneous Urticaria: New Drugs for an Old Disease.
Manti S, Giallongo A, Papale M, Parisi GF, et al · · 2022 · cited 7× · PMID 35956071 · DOI 10.3390/jcm11154453

Verify or expand the search:

Other trials of MTPS9579A

Trials testing the same drug.

NCT04092582 — A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MTPS9579A in Patients With Asthma Requiring Inhaled Co · Phase 2 · completed

Other recruiting trials for Chronic Spontaneous Urticaria

Currently open trials in the same condition.

NCT07316114 — A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spont · recruiting
NCT07358364 — Remibrutinib in Real-world Clinical Practice · recruiting
NCT07358780 — Remibrutinib in Real-world Clinical Practice - a US Sub-study · recruiting
NCT07408219 — A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients · recruiting
NCT07219615 — A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. · Phase 2 · recruiting

Other Genentech, Inc. trials

Trials by the same sponsor.

NCT06984341 — A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in P · Phase 1 · recruiting
NCT07448038 — A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vas · Phase 2 · recruiting
NCT07425522 — A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With D · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting
NCT07214662 — A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Gire · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05129423 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Genentech, Inc.
Last refreshed: 18 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05129423.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing